Trial Profile

safety regimen of RTT-1 (ELEANOR)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 04 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RTT 1 (Primary)
Indications Rett syndrome
Focus Adverse reactions

Most Recent Events

04 Nov 2025 New trial record
26 Aug 2025 According to the CURE GABA-A Media Release, Grann Pharmaceuticals has completed the initial safety regimen of RTT-1 (ELEANOR) in Eleanor as its very first patient.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com